IC PHARMA
ActiveSummary
IC PHARMA has been active since 2014 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €500,272 and a net result of €128,641. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 18% of 6,030 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
28-01
NBB filing
Annual accounts filed
financial year 2025 · full format
2025
30-06
Financial
Equity above €500,000equity €500,272 ▲1.8%
5 profitable years in a row build equity to €500,272.
28-02
NBB filing
Annual accounts filed
financial year 2024 · full format · 28 days late
2024
29-01
NBB filing
Annual accounts filed
financial year 2023 · full format
2023
13-02
NBB filing
Annual accounts filed
financial year 2022 · full format · 13 days late
2021
30-12
NBB filing
Annual accounts filed
financial year 2021 · full format
30-06
Financial
Back to profitnet €350,108
Net result €350,108 after one loss-making year.
30-06
Financial
Equity above €200,000equity €331,790 ▲226%
Equity rises from €101,682 to €331,790.
28-02
NBB filing
Annual accounts filed
financial year 2020 · full format · 28 days late
2020
30-06
Financial
Weakest financial yearnet -€223,703
Net result drops to -€223,703, the lowest in the series; recovery starts the following year.
30-01
NBB filing
Annual accounts filed
financial year 2019 · full format
2019
25-01
NBB filing
Annual accounts filed
financial year 2018 · full format
2017
28-12
NBB filing
Annual accounts filed
financial year 2017 · full format
2016
21-12
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 9 deeds read
About the unread acts
We know of 9 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.